The genome factor in region-specific DNA damage: the DNA-reactive drug U-78779 prefers mixed A/T-G/C sequences at the nucleotide level but is region-specific for long pure AT islands at the genomic level.
Bizelesin is the first anticancer drug capable of damaging specific regions of the genome with clusters of its binding sites T(A/T)(4)A. This study characterized the sequence- and region-specificity of a bizelesin analogue, U-78779, designed to interact with mixed A/T-G/C motifs. At the nucleotide level, U-78779 was found to prefer runs of A/Ts interspersed with 1 or 2 G/C pairs, although 25% of the identified sites corresponded to pure AT motifs similar to bizelesin sites. The in silico computational analysis showed that the preferred mixed A/T-G/C motifs distribute uniformly at the genomic level. In contrast, the secondary, pure AT motifs (A/T)(6)A were found densely clustered in the same long islands of AT-rich DNA that bizelesin targets. Mapping the sites and quantitating the frequencies of U-78779 adducts in model AT island and non-AT island naked DNAs demonstrated that clusters of pure AT motifs outcompete isolated mixed A/T-G/C sites in attracting drug binding. Regional preference of U-78779 for AT island domains was verified also in DNA from drug-treated cells. Thus, while the primary sequence preference gives rise to non-region-specific scattered lesions, the clustering of the minor pure AT binding motifs seems to determine region-specificity of U-78779 in the human genome. The closely correlated cytotoxic activities of U-78779 and bizelesin in several cell lines further imply that both drugs may share common cellular targets. This study underscores the significance of the genome factor in a drug's potential for region-specific DNA damage, by showing that it can take precedence over drug binding preferences at the nucleotide level.
Herzig
Maryanne C S
MC
Cancer Therapy and Research Center, 14960 Omicron Drive, San Antonio, Texas 78245, USA.
Rodriguez
Karl A
KA
Trevino
Alex V
AV
Dziegielewski
Jaroslaw
J
Arnett
Brenda
B
Hurley
Laurence
L
Woynarowski
Jan M
JM
D000227:Adenine Nucleotides / Q000302:isolation & purification / Q000378:metabolism; D018906:Antineoplastic Agents, Alkylating / Q000737:chemistry* / Q000378:metabolism / Q000633:toxicity; D001665:Binding Sites / Q000187:drug effects / Q000235:genetics; D002467:Cell Nucleus / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D003432:Cross-Linking Reagents / Q000737:chemistry / Q000378:metabolism; D003597:Cytosine Nucleotides / Q000378:metabolism; D018736:DNA Adducts / Q000737:chemistry / Q000378:metabolism; D004249:DNA Damage; D004273:DNA, Neoplasm / Q000737:chemistry* / Q000378:metabolism; D004278:DNA, Superhelical / Q000737:chemistry / Q000378:metabolism; D004279:DNA, Viral / Q000737:chemistry* / Q000378:metabolism; D018900:Dinucleotide Repeats / Q000187:drug effects*; D000080890:Duocarmycins; D015894:Genome, Human; D006150:Guanine Nucleotides / Q000378:metabolism; D006801:Humans; D007211:Indoles / Q000737:chemistry* / Q000378:metabolism / Q000633:toxicity; D007424:Intracellular Fluid / Q000737:chemistry / Q000378:metabolism; D015203:Reproducibility of Results; D017422:Sequence Analysis, DNA; D013539:Simian virus 40 / Q000187:drug effects / Q000235:genetics; D013942:Thymine Nucleotides / Q000302:isolation & purification / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014508:Urea / Q000031:analogs & derivatives* / Q000737:chemistry* / Q000378:metabolism / Q000633:toxicity
D000227:Adenine Nucleotides; D018906:Antineoplastic Agents, Alkylating; D003432:Cross-Linking Reagents; D003597:Cytosine Nucleotides; D018736:DNA Adducts; D004273:DNA, Neoplasm; D004278:DNA, Superhelical; D004279:DNA, Viral; D000080890:Duocarmycins; D006150:Guanine Nucleotides; D007211:Indoles; D013942:Thymine Nucleotides; D014508:Urea; C072257:bizelesin